PCSK9 INHIBITOR INITIATION AMONG VETERANS ACCORDING TO THE 2018 AHA/ACC BLOOD CHOLESTEROL GUIDELINES
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)30860-3
Abstract: Proprotein convertase subtilisin/kexin type 9 inhibitor antibodies (PCSK9i) have been shown prevent cardiovascular disease events in patients with atherosclerotic cardiovascular disease (ASCVD). Analyzing the characteristics of patients who initiate and do not initiate a PCSK9i… read more here.
Keywords: veterans according; pcsk9 inhibitor; inhibitor initiation; according 2018 ... See more keywords
Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0274519
Abstract: Introduction Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs. Emerging findings from laboratory studies indicate that SGLT2 inhibitors can improve liver function and suppress the proliferation of hepatocellular carcinoma (HCC)… read more here.
Keywords: inhibitor initiation; sodium glucose; sglt2 inhibitor; initiation ... See more keywords